Skip to main content
. 2022 Sep 1;28(21):4714–4723. doi: 10.1158/1078-0432.CCR-22-0749

Figure 1.

Figure 1. Cohort 1 details and comparison of different HRD detection methods. A, Clinical and genomic characteristics for each sample (small numbers at the bottom represent the individual study ID of each participant), grouping based on RECIST best overall response criteria. Clinical characteristics include the different cancer types and number of prior treatments. Different intervals of PFS are shown in the third row. Genomic characteristics include BRCA1/2 mutation status, Sig3+ classification by SigMA from panel and WES data, and the GIS calculated from WES. The lighter fill color of BRCA1/2 m indicates lack of LOH. B, 2 × 2 table of Sig3 status identified from WES and panel concordance is 81%. C, 2 × 2 table of GIS calculated with scarHRD versus Sig3-status from panel data. D, Mutations of BRCA1/2 versus Sig3 status. One patient had both a BRCA1 and BRCA2 mutation. WT, wild type; Tx, therapy.

Cohort 1 details and comparison of different HRD detection methods. A, Clinical and genomic characteristics for each sample (small numbers at the bottom represent the individual study ID of each participant), grouping based on RECIST best overall response criteria. Clinical characteristics include the different cancer types and number of prior treatments. Different intervals of PFS are shown in the third row. Genomic characteristics include BRCA1/2 mutation status, Sig3+ classification by SigMA from panel and WES data, and the GIS calculated from WES. The lighter fill color of BRCA1/2mut indicates lack of LOH. B, 2 × 2 table of Sig3 status identified from WES and panel concordance is 81%. C, 2 × 2 table of GIS calculated with scarHRD versus Sig3 status from panel data. D, Mutations of BRCA1/2 versus Sig3 status. One patient had both a BRCA1 and BRCA2 mutation. Tx, therapy; WT, wild type.